A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design

Overview of attention for article published in Frontiers in Nephrology, May 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#16 of 152)
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 17 X users

Readers on

mendeley: 5 Mendeley

Summary X

So far, Altmetric has seen 22 X posts from 17 X users, with an upper bound of 53,062 followers.

A RCT of preemptive #rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol & study design https://t.co/zJ7wUwGSAq @FrontPediatrics #FSGS #Transplant @priyagoose @rheault_m @GbadegesinLab @Har

08 Sep 2023

Reply Repost Favourite

RT @FrontNephrology: New Research: A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomeruloscle…

15 May 2023

Reply Repost Favourite

New Research: A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design #Nephrology https://t.co/iwq4ed2wnW

15 May 2023

Reply Repost Favourite

RT @ASPNeph: A RCT of Preemptive #Rituximab to Prevent Recurrent #FSGS Post-Kidney #Transplant (PRI-VENT FSGS): Protocol and Study Design h…

24 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 18 additional X posts.